Suppr超能文献

通过泰克他林时间测定法测量的活化部分凝血活酶时间(APTT)抵抗:与基于APTT的方法的比较。

APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.

作者信息

Hoagland L E, Triplett D A, Peng F, Barna L

机构信息

Muncie Center for Medical Education, Indiana University School of Medicine, USA.

出版信息

Thromb Res. 1996 Sep 1;83(5):363-73. doi: 10.1016/0049-3848(96)00146-6.

Abstract

Protein C is a major regulatory protein critical to physiologic anticoagulation. When activated, it selectively degrades the activated forms of factors V and VIII, thereby, down-regulating blood coagulation. Using an activated partial thromboplastin time (APTT) assay, Dahlback et al. recently reported that some individuals with thrombophilia show a poor in vitro anticoagulant response to activated protein C (APC-Resistance). Subsequent studies identified a point mutation in the gene for factor V as the underlying cause of APC-Resistance. The incidence of APC-Resistance in patients with recurrent thromboembolic events approaches 50%. The APC-Resistance phenotype is also present in approximately 5% of normal Caucasian subjects. In an attempt to develop a more sensitive and specific test system, we evaluated an assay based on Textarin(Pentapharm, Basel, Switzerland). Textarin, a protein fraction of Pseudonaja textilis venom (Australian Eastern Brown Snake) activates prothrombin in the presence of phospholipid (PL), factor V and calcium ions. Based on Textarin's requirement for factor V, we developed a Textarin time assay to test for APC-Resistance. We evaluated this test system in normal subjects and the following patient populations: stable orally anticoagulated, previously diagnosed factor V Leiden, and therapeutically heparinized samples. We found the Textarin assay to be a sensitive and specific test system to identify APC-Resistance. The phenotypic Textarin APC-Resistance test correlated more closely with the genotypic abnormality of factor VR506Q than the APTT-APC-Resistance test.

摘要

蛋白C是生理抗凝过程中一种关键的主要调节蛋白。被激活后,它能选择性地降解因子V和因子VIII的活化形式,从而下调血液凝固。达尔巴克等人最近使用活化部分凝血活酶时间(APTT)检测法报告称,一些血栓形成倾向患者对活化蛋白C表现出较差的体外抗凝反应(APC抵抗)。随后的研究确定因子V基因中的一个点突变是APC抵抗的根本原因。复发性血栓栓塞事件患者中APC抵抗的发生率接近50%。在正常白种人受试者中,约5%也存在APC抵抗表型。为了开发一种更灵敏、特异的检测系统,我们评估了一种基于替克他林(瑞士巴塞尔Pentapharm公司)的检测方法。替克他林是澳大利亚东部棕蛇毒液的一种蛋白成分,在磷脂(PL)、因子V和钙离子存在的情况下可激活凝血酶原。基于替克他林对因子V的需求,我们开发了替克他林时间检测法来检测APC抵抗。我们在正常受试者以及以下患者群体中评估了该检测系统:口服抗凝稳定的患者、先前诊断为因子V Leiden的患者以及接受肝素治疗的样本。我们发现替克他林检测法是一种用于识别APC抵抗的灵敏且特异的检测系统。与APTT-APC抵抗检测相比,表型替克他林APC抵抗检测与因子V R506Q的基因异常相关性更强。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验